TEVIMBRA
DEAD

Serial Number

79228266

Owner

NOVARTIS AG

Filing Date

Jan 15, 2018

Add to watchlist:

No watchlists yet
View on USPTO

TEVIMBRA Trademark

Serial Number: 79228266 • Registration: 5537974

TEVIMBRA is a trademark filed by NOVARTIS AG on January 15, 2018. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently no longer active.

Owner Contact Info

NOVARTIS AG (7,171 trademarks)

CH-4002
BASEL , CH

Entity Type: 03

BeiGene Switzerland GmbH (32 trademarks)

Aeschengraben 27

Entity Type: 99

BeOne Medicines I GmbH (66 trademarks)

Aeschengraben 27
Basel 4051 , CH

Entity Type: 27

Trademark Details

Filing Date

January 15, 2018

Registration Date

August 14, 2018

Published for Opposition

May 29, 2018

Cancellation Date

May 25, 2021

Goods & Services

Anti-infectives; anti-inflammatories; antibacterial pharmaceuticals; antibiotics; antifungal preparations; antivirals; cardiovascular pharmaceuticals; dermatological pharmaceutical preparations; inhaled pharmaceutical preparations for the prevention and treatment of respiratory diseases and disorders; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations and substances for the prevention and treatment of gastrointestinal diseases; pharmaceutical preparations for the prevention and treatment of diseases and disorders of the autoimmune system, the metabolic system, the endocrine system, the musculo-skeletal system and the genitourinary system; pharmaceutical preparations for use in hematology and in tissue and organ transplantation; pharmaceutical preparations for the prevention and treatment of eye diseases and conditions; pharmaceutical preparations for the prevention and treatment of heart rhythm disorders; pharmaceutical preparations for the prevention and treatment of immune system related diseases and disorders; pharmaceutical preparations for the prevention and treatment of kidney diseases; pharmaceutical preparations for the prevention and treatment of diabetes; pharmaceutical preparations for the prevention and treatment of hypertension; pharmaceutical preparations for the prevention and treatment of skin disorders; pharmaceutical preparations for use in dermatology; pharmaceutical preparations for use in urology; pharmaceutical preparations for ophthalmological use; pharmaceutical preparations for the prevention and treatment of cancer and tumors; pharmaceutical preparations for the prevention and the treatment of allergies; pharmaceutical preparations for the prevention and treatment of bone diseases; pharmaceutical preparations for the prevention and treatment of respiratory diseases and asthma

Filing History

CHANGE OF NAME/ADDRESS REC'D FROM IB
Jul 7, 2025 ADCH
CHANGE OF OWNER RECEIVED FROM IB
Mar 2, 2024 CHLD
NOTIFICATION PROCESSED BY IB
Nov 13, 2022 GPNX
NOTIFICATION PROCESSED BY IB
Jul 24, 2022 GPNX
CORRECTION FROM THE IB EXAMINED, NO ACTION IS NEEDED
May 31, 2022 CORN
CORRECTION TRANSACTION RECEIVED FROM IB
Nov 14, 2021 CRCV
NOTIFICATION OF EFFECT OF CANCELLATION OF INTL REG MAILED
Jun 12, 2021 DENC
DEATH OF INTERNATIONAL REGISTRATION
Jun 12, 2021 DETH
NOTIFICATION PROCESSED BY IB
Oct 6, 2018 GPNX
FINAL DISPOSITION NOTICE SENT TO IB
Sep 19, 2018 FICS
FINAL DISPOSITION PROCESSED
Sep 19, 2018 FIMP
GRANT OF PROTECTION CREATED, TO BE SENT TO IB
Sep 13, 2018 GPAR
REGISTERED-PRINCIPAL REGISTER
Aug 14, 2018 R.PR
NOTIFICATION PROCESSED BY IB
Jun 2, 2018 GPNX
PUBLISHED FOR OPPOSITION
May 29, 2018 PUBO
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
May 16, 2018 OPNS
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
May 16, 2018 OP2R
NOTICE OF PUBLICATION
May 9, 2018 NPUB
APPROVED FOR PUB - PRINCIPAL REGISTER
Apr 26, 2018 CNSA
DATA MODIFICATION COMPLETED
Apr 26, 2018 DMCC
ASSIGNED TO LIE
Apr 25, 2018 ALIE
ASSIGNED TO EXAMINER
Apr 25, 2018 DOCK
APPLICATION FILING RECEIPT MAILED
Mar 17, 2018 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Mar 13, 2018 NWOS
LIMITATION FROM ORIGINAL APPLICATION ENTERED
Mar 12, 2018 LIMI
SN ASSIGNED FOR SECT 66A APPL FROM IB
Mar 8, 2018 REPR